The medical device maker raised the money in an Edwards Lifesciences-led round as part of an agreement that could involve Edwards acquiring the company.
CardioKinetix, the US-based developer of a catheter-based treatment for heart failure, raised $50m in a late-stage round led by heart valve producer Edwards Lifesciences on Monday.
The round also included US Venture Partners, Tekla Healthcare Investors, Tekla Life Sciences Investors, SV Life Sciences, Panorama Capital, New Leaf Venture Partners and Lexington Private Equity, all of which took part as returning investors.
Edwards made the investment as part of an agreement that gives it the right to acquire CardioKinetix based on…
